Get the Stockscreener App
13.99
0.29%
-0.04
After Hours:
13.96
-0.03
-0.21%
Entrada Therapeutics Inc stock is traded at $13.99, with a volume of 79,158.
It is down -0.29% in the last 24 hours and up +10.24% over the past month.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
See More
Previous Close:
$14.03
Open:
$13.99
24h Volume:
79,158
Relative Volume:
0.37
Market Cap:
$535.60M
Revenue:
$25.42M
Net Income/Loss:
$-143.75M
P/E Ratio:
-4.0307
EPS:
-3.4709
Net Cash Flow:
$-129.55M
1W Performance:
-2.30%
1M Performance:
+10.24%
6M Performance:
+126.01%
1Y Performance:
+77.76%
1-Day Range:
$13.74
$14.24
1-Week Range:
$13.34
$14.49
52-Week Range:
$4.93
$14.49
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
13.99 | 537.13M | 25.42M | -143.75M | -129.55M | -3.4709 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-11-26 | Initiated | Guggenheim | Buy |
| Jan-28-26 | Initiated | Oppenheimer | Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
View All
Entrada Therapeutics Inc Stock (TRDA) Latest News
Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week HighShould You Buy? - MarketBeat
Sell Signal: Can Entrada Therapeutics Inc deliver consistent EPS growth2026 Buyback Activity & Long-Term Safe Investment Plans - baoquankhu1.vn
How Entrada Therapeutics Inc. (TRDA) Affects Rotational Strategy Timing - Stock Traders Daily
Investment Report: Can Entrada Therapeutics Inc deliver consistent EPS growth2026 Gainers & Verified Chart Pattern Signals - baoquankhu1.vn
TRDA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Investor Mood: Does Entrada Therapeutics Inc have declining or rising EPS2026 AllTime Highs & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Entrada Therapeutics : Corporate Presentation April 2026 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN) - The Globe and Mail
Entrada Therapeutics (NASDAQ:TRDA) Sets New 52-Week High on Analyst Upgrade - MarketBeat
Entrada Therapeutics Q2 Data Could Drive Platform Differentiation, Oppenheimer Says - marketscreener.com
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Adjusts Price Target on Entrada Therapeutics to $23 From $21, Maintains Outperform Rating - marketscreener.com
TRDA PE Ratio & Valuation, Is TRDA Overvalued - Intellectia AI
Entrada Therapeutics (NASDAQ:TRDA) CFO Sells $32,375.00 in Stock - marketbeat.com
Insider Sell Alert: Kory Wentworth Sells Shares of Entrada Thera - GuruFocus
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock By Investing.com - Investing.com Canada
Wentworth, Entrada Therapeutics CFO, sells $32375 in TRDA stock - Investing.com
Entrada Therapeutics (TRDA) CFO sells 2,500 shares under 10b5-1 plan - Stock Titan
(TRDA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
TRDA (NASDAQ: TRDA) insider 10b5‑1 sales listed, 11,388-share trade noted - Stock Titan
Entrada Therapeutics (NASDAQ:TRDA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail
Cantor Fitzgerald Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-03-31 23:31:11 - baoquankhu1.vn
Risk Analysis: Will Entrada Therapeutics Inc benefit from rising consumer demand2026 Top Decliners & Long-Term Growth Plans - baoquankhu1.vn
Pullback Watch: Is Entrada Therapeutics Inc still a buy after recent gains2026 Retail & Capital Efficient Trade Techniques - baoquankhu1.vn
Entrada Therapeutics (NASDAQ:TRDA) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Big Picture: Can Entrada Therapeutics Inc deliver consistent EPS growthTrade Analysis Report & Weekly Breakout Stock Alerts - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON) - The Globe and Mail
Hedge Fund Bets: Can Entrada Therapeutics Inc outperform under higher oil prices2026 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
If You Invested $1,000 in Entrada Therapeutics, Inc. (TRDA) - Stock Titan
Responsive Playbooks and the TRDA Inflection - Stock Traders Daily
Gainers Report: Can Entrada Therapeutics Inc ride the EV wave2026 Sector Moves & Weekly Setup with ROI Potential - baoquankhu1.vn
Pullback Watch: Is Entrada Therapeutics Inc benefiting from innovation trends2026 Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Aug EndMonth: How does Entrada Therapeutics Inc compare to its peersPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
This Olema Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Trading Recap: Will Entrada Therapeutics Inc benefit from rising consumer demandGlobal Markets & Verified Momentum Stock Watchlist - baoquankhu1.vn
Harmony Biosciences (NASDAQ:HRMY) and Entrada Therapeutics (NASDAQ:TRDA) Critical Review - Defense World
Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) COO Sells 3,116 Shares of Stock - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 5,089 Shares - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) CFO Kory James Wentworth Sells 11,388 Shares - MarketBeat
Entrada Therapeutics (TRDA) CFO sells 16,477 shares under 10b5-1 plan - Stock Titan
Understanding the Setup: (TRDA) and Scalable Risk - Stock Traders Daily
Entrada Therapeutics (NASDAQ:TRDA) Hits New 1-Year HighTime to Buy? - MarketBeat
Kory Wentworth sells TRDA shares via 10b5-1 plan (TRDA) reported to SEC - Stock Titan
Aug Breakouts: Will Entrada Therapeutics Inc benefit from rising consumer demand2026 Gainers & Entry Point Confirmation Alerts - baoquankhu1.vn
Aug Volume: How does Entrada Therapeutics Inc compare to its peersJuly 2025 Final Week & Precise Buy Zone Identification - baoquankhu1.vn
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Kory James Wentworth Sells 7,988 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock - MarketBeat
Entrada Therapeutics (TRDA) CFO executes planned stock sale - Stock Titan
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):